The study that changed everything — and why it was wrong

In 2002 a single study convinced a generation of women and doctors that HRT causes breast cancer. Millions of women stopped treatment overnight. The study had serious flaws that took years to unravel. This is the full story — and what it means for you.

Rose

"This is the page I wish had existed when my doctor would not discuss HRT with me. I was living it — confused, dismissed, and trying to make sense of conflicting information. The research was out there but nobody had put it in plain language. Here it is. Share it with your doctor if you need to."

What happened in 2002

The Womens Health Initiative (WHI) study

In July 2002, the Womens Health Initiative study was stopped early and its results published in JAMA with immediate alarm. The headlines were unambiguous: HRT causes breast cancer. HRT causes heart disease. Women should stop immediately.

The immediate consequences

HRT prescriptions fell by 66% within a year. Millions of women stopped treatment overnight — many in distress. Doctors stopped offering it. Medical schools stopped teaching it as first-line treatment. The FDA required a black box warning on all HRT products. A generation of women went undertreated for the next two decades.

What was wrong with the study

The wrong women

The average age of women in the WHI study was 63 — more than a decade past menopause. The women who typically take HRT start during perimenopause, in their late 40s or early 50s. Starting HRT a decade after menopause produces very different outcomes than starting it during the transition. The study drew conclusions about women it did not study.

The wrong HRT

The study used one specific combination — oral conjugated equine estrogen (Premarin, derived from horse urine) plus a synthetic progestogen called medroxyprogesterone acetate (MPA, sold as Provera). This is not the same as modern transdermal estrogen applied through the skin, and it is not the same as micronised progesterone — the body-identical form now widely used. The study condemned all HRT based on one old formulation.

The misleading statistics

The increased breast cancer risk was reported in relative terms — "26% increased risk" — which sounds alarming. In absolute terms it was 8 additional cases per 10,000 women per year. That is a real but small risk — comparable to the risk from drinking one to two glasses of wine daily or being overweight. The relative risk framing made it sound far more significant than it was.

The buried finding

The estrogen-only arm of the same WHI study — for women who had had a hysterectomy and did not need progestogen — showed a reduction in breast cancer risk. Estrogen alone, in this study, appeared protective. This finding received almost no media coverage. The entire HRT narrative was shaped by the combined arm while this critical nuance was ignored.

What filled the gap

The move to antidepressants

As HRT prescriptions collapsed, SSRIs and SNRIs were successfully repositioned as the treatment for menopausal symptoms — particularly hot flashes and mood changes. Paroxetine (Brisdelle) received FDA approval specifically for hot flash treatment. Millions of women were prescribed antidepressants for what was fundamentally a hormonal condition.

SSRIs reduce hot flash frequency by approximately 50-60%. HRT reduces it by 85-90%. SSRIs do not address vaginal dryness, joint pain, bone density loss, or cardiovascular risk. SSRIs have their own significant side effects — sexual dysfunction in 30-40% of users, weight gain, and discontinuation syndrome. The women who could not access HRT after 2002 were offered a less effective treatment with its own serious trade-offs, for a condition that had a better answer.

What the evidence actually shows

The revised picture — 20+ years of reanalysis

The timing hypothesis (critical window)

Women who start HRT within 10 years of menopause or before age 60 have substantially different — and better — outcomes than those who start later. The WHI studied late starters. For women in the critical window, HRT appears to reduce cardiovascular risk, not increase it. This is now called the timing hypothesis and is supported by multiple subsequent studies.

Micronised progesterone changes the picture

The French E3N cohort study and other large observational studies show that combined HRT using micronised progesterone — the body-identical form — carries significantly lower breast cancer risk than combined HRT using synthetic progestogens like MPA. The UK and European guidelines have updated to prefer micronised progesterone for this reason.

Transdermal estrogen and clot risk

Oral estrogen increases clot risk because it passes through the liver. Transdermal estrogen — patches, gels, sprays — does not carry this risk because it bypasses the liver. This distinction was not made in the WHI study, which used oral estrogen. Current guidelines prefer transdermal estrogen for most women for this reason.

The studies that followed

The Danish Osteoporosis Prevention Study (DOPS), the Kronos Early Estrogen Prevention Study (KEEPS), the Early versus Late Intervention Trial with Estradiol (ELITE), and multiple large observational studies have all produced findings substantially more reassuring than the WHI. The Menopause Society, the British Menopause Society, and the International Menopause Society have all published updated position statements reflecting this revised evidence.

Putting the risk in context

Things that carry similar or greater breast cancer risk than combined HRT

Drinking 1-2 glasses of wine daily